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Acute necrotizing encephalopathy (ANE) is a rare but distinctive type of acute encephalopathy with global distribution. Occurrence
of ANE is usually preceded by a virus-associated febrile illness and ensued by rapid deterioration. However, the causal relationship
between viral infections andANE and the exact pathogenesis of ANE remain unclear; both environmental and host factorsmight be
involved.Most cases of ANE are sporadic and nonrecurrent, namely, isolated or sporadic ANE; however, few cases are recurrent and
with familial episodes. The recurrent and familial forms of ANE were found to be incompletely autosomal-dominant. Further the
missense mutations in the gene encoding the nuclear pore protein Ran Binding Protein 2 (RANBP2) were identified. Although the
clinical course and the prognosis of ANE are diverse, the hallmark of neuroradiologicmanifestation of ANE ismultifocal symmetric
brain lesions which are demonstrated by computed tomography (CT) or magnetic resonance imaging (MRI). The treatment of
ANE is still under investigation. We summarize the up-to-date knowledge on ANE, with emphasis on prompt diagnosis and better
treatment of this rare but fatal disease.
1. Introduction
Acute necrotizing encephalopathy (ANE), first proposed by
Mizuguchi et al. in 1995, is a rare but distinctive type of acute
encephalopathy with global distribution [1]. It is generally
considered to be a parainfectious disease that is triggered
mainly by viral infections [1]. Most initially reported ANE
cases were Japanese and Taiwanese children, leading to the
suspicion that the disease was related to racial factors [2].
However, an increasing number of cases were later reported
inWestern countries [3–13] including adult ones [14, 15], sug-
gesting a global distribution of ANE without racial predilec-
tion. ANE has yet been recognized primarily as a clinicora-
diologic disorder with unknown etiology.We herein summa-
rize the up-to-date knowledge of the etiology, pathogenesis,
clinical manifestations, and radiological features, as well as
current treatment and prognosis of ANE.
2. Etiology and Pathogenesis of ANE
At present, the etiology and the pathogenesis of ANE remain
incompletely clear. Both environmental factors, which may
contribute to the antecedent infections, and host factors
such as individual susceptibility or alterations of genes might
be involved [16]. Usually, ANE develops secondary to viral
infections, including influenza A and influenza B, novel
influenza A (H1N1), parainfluenza, varicella, human her-
pesvirus 6 and herpesvirus 7 (HHV-6 and HHV-7), enter-
ovirus, novel reovirus train (MRV2Tou05), rotavirus, herpes
simplex virus, rubella, coxsackie A9, and measles, among
which the influenza virus and HHV-6 are most common
[5, 9–13, 17–34]. Prodromal viral infections appear to play
a critical role in the initiation of ANE. Despite the various
antecedent infections, ANE is not considered to be an inflam-
matory encephalitis.
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Although polymerase chain reaction (PCR) for some
viruses was positive in cerebrospinal fluid (CSF) in some
reports, there was no clue for encephalitis through autopsic
pathological examinations, which showed notably minimal
brain inflammation in relation to the marked parenchymal
abnormality [3, 4, 20, 22, 25, 35]. Moreover, CSF pleocytosis
is usually absent in patients with ANE. Additionally, no dif-
ference was noted with regard to clinical features and out-
come except for the more frequent brain stem lesions in
ANE secondary to influenza as compared with noninfluenza
illnesses [36]. In this regard, development of ANE seems
independent of the type of infectious agents.
Although the exact pathogenesis of ANE remains ob-
scure, the most prevalent hypothesis is the hypercytokine-
mia, that is, “cytokine storm” [37–39]. Individuals suffering
from ANE often have an exaggerated immune response to
various viral infections by producing elevated proinflamma-
tory cytokines resembling systemic inflammatory response
syndrome (SIRS) [37, 38]. The “cytokine storm” results in
systemic symptoms, such as liver dysfunction, acute renal
failure, shock, and disseminated intravascular coagulation
[37–39]. In the nervous system, it leads to brain injury
through alteration of vessel wall permeability without vessel
wall disruption [37, 38]. According to this hypothesis, ANE
is an encephalopathy concomitant with systemic immune
imbalance. Flow cytometric analysis on peripheral blood
lymphocytes of patients with ANE revealed high proportion
of CD56+ natural killer (NK) cells during the recovery phase
[28]. These cells produced a high level of cytokines, suggest-
ing that NK cellsmight be associated with the pathogenesis of
ANE [28]. In addition, several lines of evidence showed that
levels of cytokines were elevated in the serum and/or CSF in
different virus-associated ANE including interleukin- (IL-) 6,
tumor necrosis factor-alpha (TNF-𝛼), IL-10, IL-15, IL-1𝛽,
soluble TNF receptor (sTNFR), and interferon-gamma (IFN-
𝛾) [18, 20, 23, 26, 28, 38, 40–44]. IL-6 and TNF-𝛼were critical
among these cytokines, because the former was neurotoxic
at high concentrations, whereas the latter could damage the
endothelium of the central nervous system. Hypercytokine-
mia engenders proteolytic destruction of the blood-brain
barrier (BBB) through the action of trypsin and the activation
of matrix metalloprotease-9, which subsequently increases
vascular permeability and causes brain edema, petechial
hemorrhage, and necrosis [38, 44, 45]. Except for the above
viral infections, ANE may also develop secondary to diph-
theria, tetanus toxoid, andwhole-cell pertussis (DPTw) vacci-
nation [26]. The DPTw vaccination might result in increased
production of cytokines and cause the alteration of vessel wall
permeability, leading to local breakdown of BBB [38, 44–47].
ANEwas initially believed to bewith geographic predilec-
tion, whereas it was later foundwith global distribution [2, 3].
Most ANE cases are sporadic and nonrecurrent, namely,
isolatedANE.However, few cases of recurrent and/or familial
episodes have been reported suggestive of an inherited
disposition [8, 48, 49]. In addition to environmental factors,
host factors may contribute to the development of ANE as
well. Genetic background, for example, human leukocyte
antigen (HLA)DRB/HLADQBgenesmight contribute to the
pathogenesis of ANE [17]. Neilson and colleagues reported
a case series with incompletely penetrant and autosomal-
dominant acute encephalopathy identical to ANE; the dom-
inance was estimated to be at 50% and recurrent episodes
occurred in half of the affected individuals [48]. Further, by
performing home linkage analysis they mapped the disease
interval to human chromosome 2q12.1-2q13 sequencing for
candidate genes (BCL2L11, ST6GalII, CHT1, and FLJ20019)
that are involved in apoptosis, viral recognition, choline
transport, and electron transport, whereas they failed to find
anymutations [49].Until 2009, their study had been extended
to include 16 probands with familial ANE. The missense
mutations in the gene encoding the nuclear pore protein Ran
Binding Protein 2 (RANBP2) were found to be the suscepti-
bility alleles for familial and recurrent cases of ANE, and they
proposed naming this type of ANE as “ANE1” [50]. Since the
relationship between ANE and the RANBP2 gene was identi-
fied, there have been several reports on recurrent or familial
cases, while the mechanism of this mutation leading to
pathology remains unclear [20, 22, 51]. RANBP2 is located on
the cytoplasmic surface of the nuclear pore, and its numerous
functions throughout the cell cycle have been found, which
include facilitation of the protein transportation and sumoy-
lation of protein cargoes during interphase, intracellular traf-
ficking, or energymaintenance in certain type of cells, includ-
ing neurons, and contribution to the nuclear envelop break-
down as well as facilitation of sister chromatid resolution
duringmitosis [50].TheRANBP2mutationsmay affect intra-
cellular trafficking ofmitochondria or energy production and
lipid peroxidation. It may also affect other processes includ-
ing viral entry, antigen presentation, cytokine signaling,
immune responses, and BBBmaintenance [50]. However, the
RANBP2missense mutations were not the sole susceptibility
alleles for familial or recurrent ANE which accounted for
75% of the case series, because cases with recurrent ANE
but without RANBP2 missense mutations have also been
reported [50–52]. Of note is that gray matter heterotopia and
ANEmay occur in patients with trichothiodystrophy (TTD),
an autosomal-recessive disorder, arousing the hypothesis that
ANE and TTD share a common genetic background [53].
Except for the above mentioned environmental and host
factors, Shinohara et al. found that variations of the carnitine
palmitoyl transferase II gene (CPT II) were associated with
ANE [54]. Kumakura and colleagues found the thermolabile
phenotype of carnitine palmitoyl transferase II in an ANE
patient, and they speculated that it decreased enzymatic
activities which reduced the utilization of mitochondrial fuel
during high-grade fever [45]. Further, the impaired mito-
chondrial 𝛽-oxidation and the generation of adenosine
triphosphate in the cerebral microvascular endothelial cells
(ECs) engendered the increasing permeability of the vascular
wall and the development of brain edema [45].The increasing
permeability of the vascular wall could be caused by genetic
factors of susceptibility to energy failure in addition to patho-
physiologic factors of hypercytokinemia.
Another interesting finding was the ephrin type B recep-
tor 2 (EphB2), a novel cell-surface autoantigen which had
critical functions to neuronal and ECs [55]. EphB2 was
expressed by human brain microvascular ECs, which was
found as a target of autoantibody from a patient with
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Figure 1: Clinical course of acute necrotizing encephalopathy (ANE). Survivors of ANE go through three phases during the clinical course
including prodromal stage, period of acute encephalopathy, and recovery stage. In the prodromal stage, the common symptoms include
cough, vomiting, diarrhea, skin erythra mainly due to various viral infections. Soon after, the dysfunction of the brain gradually appeared
during the acute encephalopathy stage, for example, disturbance of consciousness, seizures, focal deficits. If survived, patients of ANE would
go through the third phase, so-called recovery stage, and most patients left with different neurological sequelae while a few could recover
completely.
ANE complicated with systemic lupus erythematosus (SLE).
Anti-EphB2 antibody, however, was not detectable in any
SLE patients without ANE, indicative of its potentials as a
biomarker of ANE. The possible mechanisms are as follows:
(1) anti-EphB2 antibodies damage vascular ECs which results
in breakdown and increased permeability of BBB; (2) when
BBB is breached, anti-EphB2 antibodies exudate into brain
tissue and bind neurons and neuroglia causing neuronal dys-
function and cell death [55]. However, the pathomechanism
of anti-EphB2 antibodies in ANE remains largely unknown.
3. Clinical Manifestations of ANE
Patients with ANE have neither specified symptoms nor typ-
ical neurological signs. Comparisons of the clinical features
between Asian and non-Asian patients revealed homogeneity
of the disease worldwide [12]. In addition to prodromal
symptoms due to different viral infections, which include
fever, signs of upper respiratory tract infections and gastroen-
teritis, and erythema, patients with ANE often have signs
of SIRS like shock, multiple organ failure (MOF), and dis-
seminated intravascular coagulation (DIC) [17, 33, 56]. With
the development of ANE, brain dysfunctions may present as
seizures, disturbance of consciousness, and focal neurological
deficits [3, 17–26, 57]. Of note, however, is that none of
the above manifestations are specific to ANE. Laboratory
findings vary from case to case, while some could be used for
differential diagnosis, such as abnormalities of liver function
without hyperammonemia, hypoglycemia, or lactic acidosis.
Moreover, the protein levels of CSF and platelet count could
be a predictor of the prognosis of the disease [3, 17, 22, 31, 58].
The clinical course of ANE is fulminant and diverse, from
a mild form with completely recovery or mild sequelae to
a severe form with a high mortality [25, 31, 37, 59, 60].
Usually, survivors of ANE go through three phases during
the clinical course including prodromal stage, period of acute
encephalopathy, and recovery stage as shown in Figure 1 [5,
7, 9, 10, 18–20, 23, 29, 31, 35, 61–63]. Due to the decreased
incidence of autopsies, the diagnosis of ANE was mainly
based on characteristic neuroradiologic findings [3, 64, 65].
However, diagnosis can only be established pending the
exclusion of other resembling diseases. Except for the genetic
background, familial ANE is similar to isolated ANE in terms
of clinical and radiologic features [50]. However, recurrences
produce more severe functional impairments [8, 48–51, 61].
The diagnostic criteria and differential diagnoses of ANE are
shown in Section 8.
4. Neuroradiologic Features of ANE and
Its Clinical Significance
The hallmark of neuroradiologic manifestations of ANE
is multifocal, symmetric brain lesions involving both the
gray matter and the white matter that are demonstrated by
computed tomography (CT) or magnetic resonance imaging
(MRI), consistent with histopathologic findings via autopsy
[2]. The topographic distributions are remarkably similar
among patients with ANE, including thalami, brain stem,
cerebral white matter, and cerebellum [2, 18–25, 64, 65].
Bilateral thalami are typically involved in all patients with
ANE, serving as a distinctive feature of ANE [2, 58]. Spinal
cord may occasionally be involved as well [20, 61, 66].
Neuroradiologic manifestations are characterized by dy-
namic changes during the clinical course corresponding to
pathophysiological changes from edema to petechial hemor-
rhage and then to necrosis [1, 2]. Regression or recovery of the
brain lesions is possible for survivors [1–4]. Hereinwe explain
the dynamic imaging changes in the brain of ANE by exhibit-
ing the neuroimages of our patient with ANE (Figures 2 and
3). Lesions in the brain are edematous and combined with
mass effect at the onset of ANE. Hypodensities are frequently
seen on CT (Figure 2(a)) and homogeneously prolonged
T
1
(Figures 2(b) and 2(c)) and T
2
(Figures 2(d) and 2(e))
relaxation time (Figures 2(b) and 2(c)) of the brain lesions
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Figure 2: Dynamic changes of magnetic resonance imaging (MRI) of a patient with acute necrotizing encephalopathy (ANE). (a) was
computerized tomography (CT) at onset; (b) and (c), (d) and (e), and (f) and (g) were, respectively, the T
1
-weighted image (T
1
WI), T
2
WI,
and fluid attenuated inversion recovery (FLAIR) image at onset which showed lesions on bilateral thalamus and brain stem (blue arrow); (h)
and (i), (g) and (k), and (l) were, respectively, the T
1
WI, T
2
WI, and FLAIR imaging of follow-up which revealed disappearance of the brain
stem lesions and impressive regression of the thalamic lesions, just left hemosiderin deposition (red arrow).
on MRI are found in most patients. Moreover, the feature
of restricted water diffusibility on diffusion MR including
diffusion-weighted imaging (DWI) and apparent diffusion
coefficient (ADC) (Figures 3(b), 3(c), 3(d), and 3(e)) can be
found in a majority of ANE patients [10, 11, 18–20, 22–26, 35–
37, 45, 67]. Gradually, with the resolution of edema and
mass effect, the feature of petechial hemorrhage and necro-
sis appears, and hypodense areas on CT become mottled
because of the irregular hyperdense spots at the center which
result from the extravasation of blood vessels or petechial
hemorrhage [35, 59]. On the corresponding T
1
-weighted
imaging (T
1
WI), increased signal intensities in the center
surrounded by the decreased signals are detected, while
T
2
-weighted imaging (T
2
WI) may reveal decreased signal
intensities that are surrounded by increased or homogeneous
increased signal intensities [5, 10, 26, 67]. Small petechial
hemorrhage is usually obscure. The T
2
∗-weighted gradient
echo imaging or the susceptibility weighted imaging (SWI) is
more sensitive in showing the petechial hemorrhage of ANE,
both of which demonstrate low signal intensities [9, 67, 68].
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Figure 3: Diffusion MRI and susceptibility weighted imaging (SWI) findings of acute necrotizing encephalopathy (ANE). (a) was the
schematic diagram of typical tricolor pattern corresponding to the thalamic lesions on (b) (a: center of thalamic lesions characterized by
hemorrhage and necrosis; b: periphery of the central thalamic lesions characterized by cytotoxic edema; c: outside portions of the thalamic
lesions suggesting vasogenic edema). (b) and (c), (d) and (e) were the apparent diffusion coefficient (ADC) and diffusion-weighted image
(DWI), respectively, at onset which suggested the bilateral thalamus and brain stem lesions (blue arrow). (f) and (g), (h) and (i) were the ADC
and DWI imaging of follow-up which revealed disappearance of the brain stem lesions and hemosiderin deposition on bilateral thalamus
(red arrow). (j), (k), and (l) were the follow-up SWI images which showed hemosiderin deposition in the bilateral thalami and the cerebella
(red arrow).
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The classical neuroimaging of ANE was “concentric/lam-
inar structure” or “tricolor pattern” or target-like appearance
[6, 22, 64, 65]. This typical manifestation is more obvious
on ADC of MRI (Figures 3(b) and 3(c)). Without the disad-
vantage of T
2
penetration effect, the center of the lesion
presents slightly high signal with low signal in the sur-
rounding of the lesion suggestive of cytotoxic edema, and its
periphery suggests vasogenic edema on ADC (Figure 3(a))
[6, 22, 64, 65]. Pathological changes of ANE may explain
the above neuroimaging manifestations. Usually, the center
of thalamic lesions is perivascular hemorrhage and necrosis
of neurons and glial cells corresponding to slightly high
signals on ADC, while the periphery of the center portion
revealed congestion of arteries, veins, and capillaries and
acute swelling of oligodendrocytes corresponding to low
signals in the surrounding, with extravasations at the edge
of the thalamic lesions corresponding to high signals in the
outermost [64]. Taken together, this concentric structure
reveals edema, petechial hemorrhage, and necrosis without
inflammatory cell infiltration or astrocytic proliferation [12,
21, 25, 32, 35, 59, 69]. It is noteworthy that the typical lesions
appear predominantly in the gray matter, especially in the
bilateral thalami [2, 64, 65]. The follow-up neuroradiologic
examinations of the survivors showed either complete recov-
ery or impressive regression of the lesions, such as atrophy,
hemosiderin deposition, and white matter cysts [4, 9, 10, 18–
20, 26, 29, 31, 34, 35, 63].
Here we present the neuroimages of an adult patient
with ANE who was admitted to our department because of
seizure and confusion (Figures 2 and 3).The imaging at onset
and during follow-up (two months later) revealed a dynamic
change. Hypodensities on CT (Figure 2(a)) and prolonged
T
1
- (Figures 2(b) and 2(c)) and T
2
(Figures 2(d) and 2(e))
relaxation time on MRI of the brain lesions could be found
at onset. These lesions were more clear on fluid attenuated
inversion recovery (FLAIR) image (Figures 2(f) and 2(g)).
At onset, laminar structure but not typical tricolor pattern
was found on the bilateral thalami by ADC (Figure 3(b)).
Figure 3(a) was a schematic diagram of the typical tricolor
pattern of the thalamic lesions (a: center of thalamic lesions
characterized by hemorrhage and necrosis; b: periphery
of the central thalamic lesions characterized by cytotoxic
edema; c: outside portions of the thalamic lesions suggesting
vasogenic edema). Besides, we could find brain stem lesions
on ADC (Figure 3(c)). While on DWI, these lesions of
bilateral thalami and brain stem (Figures 3(d) and 3(e))
appeared without laminar structure. Two months later, these
lesions of the brain stem disappeared on T
1
WI (Figure 2(i)),
T
2
WI (Figure 2(k)), FLAIR (not shown), ADC (Figure 3(G)),
and DWI (Figure 3(I)). Similarly, the lesions on bilateral
thalami resolved remarkably, except for some hemosiderin
deposition (Figure 2(h): T
1
WI; Figure 2(j): T
2
WI; Figure 2(l):
FLAIR; Figure 3(f): ADC; Figure 3(h): DWI; Figures
3(j), 3(k) and 3(l): SWI). Two months later, the patient
complained of mild paresthesia around his mouth without
any other neurological sequela. The follow-up SWI imaging
demonstrated hemosiderin deposition not only in the
bilateral thalami, but also in the brain stem and cerebellum.
Gadolinium-contrast MRI has been reported useful in
identifying lesions at the very early stage of ANE when
conventional CT, MRI, and even DWI and ADC show no
abnormalities [37].This finding suggests that alteration of the
BBB permeability might be the first step in the development
of brain lesions.The gadolinium-contrast MRI may therefore
be helpful for early diagnosis so as to initiate treatment
as early as possible and alleviate neurological sequelae of
patients [37]. However, Wong and colleagues found that not
all ANE patients presented contrast enhancement, partially
due to the difference of performing time and the severity of
the disease [65]; some unknown pathogenesis of ANE other
than the alteration of BBB permeability may also exist [65].
Due to the conflicting results of gadolinium-contrast MRI,
further studies are warranted [19, 25, 26, 37].
5. Novel Imaging Technologies and Its Clinical
Significance to ANE
Some extended or novel imaging modalities have been ap-
plied to ANE with clinical significance, which are correlated
either to the pathogenesis or to the prognosis of ANE [19,
35, 67, 70]. Moreover, these modalities may contribute to the
differential diagnosis of ANE.
Diffusion tensor imaging (DTI) is mainly used for detec-
tion of abnormal nerve fibers in the white matter. DTI
may potentially picture the microstructural changes in ANE
patients with white matter involvement and contribute to the
differentiation between ANE and other resembling diseases
as well. Chen and colleagues performed DTI in patients with
ANE and acute disseminated encephalomyelitis (ADEM)
confirmed by biopsy [70]. DTI showed unchanged fractional
anisotropy and decreased axial and radial diffusivity sugges-
tive of axonal injury without demyelinationin patients with
ANE, which was later confirmed by pathology [70]. However,
decreased fractional anisotropy, unchanged axial diffusivity,
andmarkedly increased radial diffusivity compatible with the
biopsy finding were found in patients with ADEM, indicative
of active inflammatory demyelination [70].
Magnetic resonance spectroscopy (MRS) is another novel
modality in neurological clinic. Lipid-lactate complex peak
and glutamate/glutamine complex peak on MRS, both of
whichmight be reversible or transient, were found in patients
with ANE [6, 26]. The former peak on MRS might be due
to the cell membrane damage or disintegration. While glu-
tamate, a well-known excitatory neurotransmitter that may
cause neuronal damage, might contribute to the pathogenesis
of ANE by glutamate-mediated excitotoxicity if excessive
amounts were released into the synaptic cleft. However, the
glutamate/glutamine complex peak onMRS was absent from
some ANE patients, indicating that the peak might depend
on the severity of the disease and may serve as a predictor of
outcomes in ANE patients [67].
Additionally, an ANE patient with bilateral symmetrical
thalamic lesions received a somatosensory evoked magnetic
fields (SEF) examination, suggesting normal latency and
strength of the first component elicited bymedian nerve stim-
ulation [19]. Their findings suggested that thalamus-cortical
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fibers were intact although thalamus lesions occurred. Their
finding was probably ascribed to a reversible course of BBB
breakdown and edematous process [19].
In the case of Oki et al., single photon emission computed
tomography (SPECT) using 99mTc-ethyl cysteinate dimer
(ECD) and N-isopropy-p-123I iodoamphetamine (123I-IMP)
was performed in an ANE patient on the 39th and 67th days
after disease onset [35]. The thalamic lesions presented par-
tially high signal intensity surrounded by low signal intensity
on the 34th day after disease onset, indicative of marked
hypoperfusion regardless of redistribution on delayed images
of 123I-IMP SPECT.The irreversible tissue damage despite the
recovered blood flow may explain the unfavorable prognosis
[35].
6. Treatment of ANE
There have been no recommended therapies forANE thus far.
Intensive care, symptomatic treatment and empirical treat-
ment (antiviral therapy), and immunomodulatory agents
were tested in a majority of cases [2, 18, 68, 69]. Due
to the pathogenesis of ANE, mainly the hypercytokinemia
secondary to variable viral infections through immune-
mediated mechanism, the immunomodulatory therapy, par-
ticularly the therapy that suppressed the cytokine production,
has the potential to improve the outcome of ANE. Intra-
venous glucocorticoids, immunoglobulin, and plasmaphere-
sis should be effective on the basis of the pathogenesis of ANE
[5, 20, 24, 25, 30, 57, 60, 63, 68, 69]. Among these therapies,
intravenous glucocorticoids, including methylprednisolone
and dexamethasone, were the most mentioned and stud-
ied, although empirically without systematically determined.
However, results from different studies were conflicting.
Some researchers reported that administration of steroids
within 24 hours after onset or at the early stage of the
disease was related to a better prognosis in those without
brain stem involvement [13, 18, 56]. However, in spite of
the severity of presentation and the late administration of
steroids, good outcome was still found in some patients, and
some researchers suggested that a trail of steroids should be
given to all patients with ANE [10, 17, 20]. Another study, on
the contrary, reported that ANE patients treated with steroids
had a poor outcome [33]. So far, there has been no consensus
on whether we should prescribe steroids to patients with
ANE, as well as the dosage, timing, and the duration.
Therapeutic hypothermia, another method of anticy-
tokine therapy, has been used for treating brain swelling
caused by trauma and encephalopathy [40, 71]. Therapeutic
hypothermia is pivotal to the outcome of the children with
ANE, especially if it is initiated within 12 hours after onset
[18, 23].
7. Prognosis and Its Predictors in
Patients with ANE
ANE is a progressive and devastating disease, regardless of
treatment.Theprognosis of ANE varies from complete recov-
ery to death. It was estimated that themortality ratewas about
30% and less than 10% of patients recovered completely while
the neurological sequelae were frequent in survivors [31, 52,
72]. Recently, Bassuk et al. found that the outcome of ANE in
Japan was still poor, with incidence of full recovery, mild to
moderate sequelae, severe sequelae, and death of 12.8%, 23%,
33.3%, and 28.2%, respectively [13]. Although patients with
ANE eventually have a good outcome following a gradual
improvement, the course of recovery is slow which results
in many children leaving hospital with significant neurologic
problems [12, 22, 24, 29, 38, 59]. Hitherto, ANE is still a
disabled even fatal disease which should be paid attention to.
The reason for the good outcome in some reports may be as
follows: (1) increased recognition of the mild form which is
diagnosedmainly based on the clinical symptoms, course and
radiologic findings; (2) prompt and appropriate treatment
after early diagnosis of the disease [3, 18, 19, 21, 23, 31, 60].
Several factors are deemed to be related to the prognosis
of ANE acting as predictors. For instance, age above 4 years
old was regarded as a predictor of a better outcome while
age below 1 year old was indicative a poor prognosis [3].
Moreover, themostmentioned predictive factor in themajor-
ity of reports was the laboratory examination, such as the
serum aminotransferase and protein inCSF [3], especially the
latter, which in the normal range or if was mildly increased
usually predicted a better prognosis while moderate or severe
elevation was related to a poor outcome [5, 6, 24, 26, 61, 69].
Asymmetric unilateral thalamic involvement and reversion
of the image as well were regarded as a predictor of a good
outcome while the presence of hemorrhage and localized
tissue loss on MRI would predict a poor prognosis [2, 7,
31, 58, 60, 64]. Delirious behaviors, which usually result
from brain stem lesions, were considered to be predictive
of a poor outcome [57]. The correlation between brain stem
lesions and the outcome of ANE was controversial from
different reports [12, 31, 32, 38, 44, 45, 63]. However, imaging
features seem to be related to the outcome [65]. Wong
and colleagues created a scoring system to evaluate patients
with ANE [65]. The presence of hemorrhage, cavitation, and
location of lesions including the brain stem, the white matter
(cerebral, cerebellar, or both) were awarded one point for
each of these features, except for the thalami lesions which
were 100% involved [65]. They found that the score was
related to the outcome of the patients [65]. Another ANE
severity scale (ANE-SS) which ranges from 0 to 9 points has
been developed, and presence of shock, brain stem lesions,
an age over 48 months, a platelet count below 100,000/𝜇L,
and an elevated level of CSF protein correspond to 3, 2,
2, 1, and 1 points, respectively [73]. The ANE-SS could be
a predictor for the outcome or prognosis of children with
ANE [73]. Nevertheless, some extended or novel imaging
technologies, as mentioned above, might also be a predictor
of the prognosis.
8. Diagnostic Criteria for Acute Necrotizing
Encephalopathy (ANE)
8.1. Diagnostic Criteria for ANE (Proposed byMizuguchi et al.)
[1, 2]. Diagnostic criteria for ANE are as follows:
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(1) acute encephalopathy preceded by viral febrile dis-
ease; rapid deterioration in the level of consciousness,
convulsion;
(2) increased cerebrospinal (CSF) protein without pleo-
cytosis;
(3) neuroradiologic findings for symmetric, multifocal
brain lesions involving bilateral thalami, cerebral
periventricular white matter, internal capsule, puta-
men, upper brain stem tegmentum, and cerebellar
medulla without involvement of other CNS regions;
(4) elevation of serum aminotransferase level to a vari-
able degree without hyperammonemia;
(5) exclusion of other resembling diseases:
(a) clinical differential diagnosis; toxic shock syn-
drome, hemolytic uremic syndrome, Reye syn-
drome, hemorrhagic shock and encephalopathy
syndrome, and heat stroke;
(b) radiological (or pathological) differential diag-
nosis; Leigh encephalopathy, glutaric acidemia,
methyl malonic aciduria, infantile bilateral
strial necrosis, Wernicke encephalopathy, acute
disseminated encephalomyelitis, acute hemor-
rhagic leukoencephalitis, arterial or venous
infarct, severe hypoxia or traumatic injury, tox-
ins resulting in symmetric bilateral basal gan-
glia necrosis (such as carbon monoxide, meth-
anol, 1 methyl-4 phenyl-1,2,3,6 tetrahydropyri-
dine, cyanide, manganese, carbon disulfide, and
tegretol), and some other diseases causing sym-
metric bilateral basal ganglia necrosis (such as
osmotic myelinolysis, prolonged hypotension,
Canavan disease,methylmalonic acidemia,Wil-
son disease, Juvenile Huntington disease, stria-
tonigral degeneration, and Hallervorden-Spatz
syndrome).
8.2. Diagnostic Criteria for ANE1 (Proposed by Neilson et al.)
[16, 50]. Except for the above diagnostic criteria for ANE,
simultaneously meet any of the following criteria:
(1) familial history of neurological symptoms which
might be parainfectious;
(2) recurrent encephalopathy following fever;
(3) additional MRI changes in one of the following:
medial temporal lobes, insular cortices, claustrum,
external capsule, amygdale, hippocampi, mammil-
lary, and spinal cord.
9. Conclusions
ANE is an immune-mediated disease with incompletely
recognized pathogenesis. It is underdiagnosed partially due
to the insufficient awareness. The diagnosis of ANE is mainly
based on the clinical and radiologic features pending the
exclusion of other resembling diseases. Immunomodulatory
and anticytokine therapies are promising in dealing with
ANE whereas more studies are still needed. The prognosis of
ANE is variable; however, it is still a potentially devastating
disease leading to death and severe neurological sequelae.
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